Antimicrobial safety
Cefepime neurotoxicity: a renal adjustment does not rule it out
New confusion during cefepime treatment deserves a medicine review even when a renal adjustment was documented. The June 2026 US label warns that neurotoxicity has occurred with both unadjusted and appropriately adjusted regimens.
Sources checked October 12, 2026. Independent educational content, not NABP exam questions or individual treatment advice.
Recognize the presentation before defending the dose
The label describes disturbances of consciousness including confusion, hallucinations, stupor and coma, as well as aphasia, myoclonus, seizures and nonconvulsive status epilepticus. A patient does not need a witnessed convulsion for the warning to matter.
Infection, metabolic illness and other medicines can also affect consciousness. The task is to assess the possible drug contribution alongside these causes, not to diagnose cefepime toxicity from one symptom or dismiss it because treatment is needed.
Read the renal threshold correctly
The label calls for adult dose adjustment when creatinine clearance is less than or equal to 60 mL/min. Select the regimen from the indication-specific renal table; a single reduced dose cannot be applied to every infection.
Check the current renal assessment and the regimen actually administered. A dose selected from an earlier stable value may no longer reflect the patient. The renal metric in this label is creatinine clearance, not an invitation to substitute every reported kidney number without review.
Do not treat correct adjustment as proof of safety
Most reported cases occurred in renal impairment without appropriate adjustment, but some occurred despite adjustment appropriate to the degree of impairment. That second sentence is important: a completed dose check does not close the adverse-effect investigation.
The label says most cases were reversible after discontinuation and/or hemodialysis. This describes reported management and outcomes, not a guarantee of recovery or an instruction to arrange dialysis without clinical assessment.
Make the response a clinical review, not an automatic switch
If cefepime-associated neurotoxicity occurs, the label directs discontinuation and supportive measures. The treating team must also preserve effective treatment of the infection with a suitable plan.
For an exam case, identify the warning, the kidney and dose checks, and why an apparently correct dose cannot rule it out. Do not supply a replacement antimicrobial without susceptibility, infection-site and patient evidence.
A worked case
A patient with CrCl 38 receives a documented renal-adjusted cefepime regimen. They develop new confusion and myoclonus. A colleague excludes cefepime because the dose was adjusted. Which conclusion is unsupported?
- Neurotoxicity can occur despite appropriate renal adjustment.
- Confusion and myoclonus match labeled manifestations.
- Assess the medicine contribution and other causes promptly, rather than using the dose check to exclude it.
Answer: The adjusted dose does not rule out cefepime neurotoxicity. The team needs a prompt safety and infection-treatment review.
Try it before reading the answer
Write the key fact, decision and safety check first. These are original practice exercises, not recalled exam items.
1. Does neurotoxicity require a witnessed convulsion?
No. Encephalopathy and nonconvulsive status epilepticus are among the manifestations.
2. At CrCl exactly 60, does the label require adjustment?
Yes. The threshold includes 60.
3. Does a correct adjustment exclude toxicity?
No.
Continue learning
Put the topic into a study planSources and scope
Source dates and limits matter. Follow the current official source for clinical or regulatory decisions. Examples are simplified teaching cases, not prescribing, diagnostic or compounding instructions. Check the full current guidance and individual clinical context.